购物车
- 全部删除
- 您的购物车当前为空
IDH-305 是突变选择性的、口服性的、脑渗透性的 IDH1抑制剂,靶向 IDH1 (R132) 突变。它对突变体 IDH1 亚型的选择性比野生型高 200 倍 (IC50= 27 nM (IDH1R132H), 28 nM (IDH1R132C), 6.14 µM (IDH1WT))。
为众多的药物研发团队赋能,
让新药发现更简单!
IDH-305 是突变选择性的、口服性的、脑渗透性的 IDH1抑制剂,靶向 IDH1 (R132) 突变。它对突变体 IDH1 亚型的选择性比野生型高 200 倍 (IC50= 27 nM (IDH1R132H), 28 nM (IDH1R132C), 6.14 µM (IDH1WT))。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 543 | 现货 | |
5 mg | ¥ 1,330 | 现货 | |
10 mg | ¥ 1,830 | 现货 | |
25 mg | ¥ 3,730 | 现货 | |
50 mg | ¥ 5,450 | 现货 | |
100 mg | ¥ 7,650 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 1,430 | 现货 |
产品描述 | IDH-305 is an orally available, mutation-selective, and brain-penetrant IDH1 inhibitor targeting the IDH1 (R132) mutation. IDH-305 is 200-fold more selective for mutant IDH1 isoforms than wild type with IC50s of 27 nM,28 nM and 6.14 nM for IDH1R132H, IDH1R132C and IDH1WT, respectively. |
靶点活性 | IDH1 (WT):6.14 μM, IDH1 (R132H):27 nM, IDH1 (R132C):28 nM |
体外活性 | IDH-305 抑制 HCT116-IDH1R132H /- 细胞,其中半抑制浓度(IC50)为24 nM[1]。 |
体内活性 | 经口给药, IDH-305以30-300 mg/kg的剂量每日两次,持续21天,可抑制IDH1突变的PDX黑色素瘤模型的2-HG产生及依赖2-HG的肿瘤生长[1]。 |
分子量 | 490.45 |
分子式 | C23H22F4N6O2 |
CAS No. | 1628805-46-8 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 100 mg/mL (203.90 mM) | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.